Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Laboratory Testing Consolidated into Fewer More Appropriate Systems

By LabMedica International staff writers
Posted on 15 Sep 2009
Laboratory testing is being consolidated in fewer more apt systems. More...
For example, test panels for anemia, cardiac disease, thyroid disorders, therapeutic drug monitoring, protein testing, drugs-of-abuse testing, and routine and specialty chemistry testing are being offered in one system.

An expanded portfolio of Dimension Vista systems meets the needs of all sizes of clinical laboratories. Dimension Vista 500 Intelligent Lab System, the latest addition to the family of ultra-integrated chemistry and immunochemistry systems, was recently introduced and has a test menu of more than 115 assays. The new system offers improved quality and reduced time to produce patient test results. The expanded portfolio of Dimension Vista systems meets the needs of all sizes of clinical laboratories.

The Dimension Vista 500 Intelligent Lab System has a throughput of up to 1,000 patient tests per hour. The Dimension Vista 1000T Intelligent Lab System can also be achieved by seamlessly adjoining two Dimension Vista 500 Systems. This doubles the throughput capacity to up to 2,000 tests per hour, and provides mirror back-up capabilities and increased walk-away time for laboratory personnel.

As with other Dimension Vista systems, four advanced detection technologies including photometry, nephelometry, V-Lyte electrolyte, and Loci advanced chemiluminescence are used on the systems, resulting in a broad test menu. The Loci technology allows customers access to fast, sensitive immunoassay testing and fast analytical turnaround time of 10 minutes for critical cardiac tests such as high-sensitivity Troponin I.

"We are bringing next-generation technology to mid-volume laboratory customers by leveraging the success of the Dimension Vista 1500 System, a similar integrated diagnostic testing solution for high-volume laboratories that was introduced by Siemens in 2007," said Donal Quinn, CEO at Siemens Healthcare Diagnostics (Erlangen, Germany). "The mid-volume Dimension Vista 500 System represents another major step toward improving the quality, efficiency, and time to produce patient test results by consolidating testing onto fewer, more intelligent systems."

Siemens met the U.S. Food and Drug Administration's (FDA; Silver Spring, MD, USA) regulatory requirements to sell the Dimension Vista 500 and 1000T Intelligent Lab Systems, and both instruments are CE marked. The portfolio of Dimension Vista systems also addresses the need for standardization in large hospital networks with remote or satellite laboratories, by offering standardized patient test results and operating features.

Related Links:

Siemens Healthcare Diagnostics
U.S. Food and Drug Administration




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.